Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study.

医学 中期分析 临床终点 内科学 化疗 肺癌 安慰剂 围手术期 肿瘤科 非小细胞肺癌 阶段(地层学) 随机化 外科 临床试验 病理 古生物学 替代医学 生物 A549电池
作者
Shun Lü,Lin Wu,Wei Zhang,Peng Zhang,Wenxiang Wang,Wentao Fang,Wenqun Xing,Qixun Chen,Jiandong Mei,Lin Tai Yang,Lijie Tan,Xiaohong Sun,Shidong Xu,Xiaohua Hu,Guohua Yu,Dongliang Yu,Jinlu Shan,Nong Yang,Yuping Chen,Hui Tian
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (36_suppl): 425126-425126 被引量:93
标识
DOI:10.1200/jco.2023.41.36_suppl.425126
摘要

425126 Background: Adjuvant and neoadjuvant immunotherapy have been approved by US FDA to treat early-stage NSCLC. However, the optimal neoadjuvant and adjuvant treatment, including duration of treatment, are unknown. We present the interim results of a randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of perioperative toripalimab plus chemotherapy followed by toripalimab maintenance vs chemotherapy in resectable stage III NSCLC. Methods: Patients with stage II/III resectable NSCLC, without EGFR/ALK alterations for non-squamous NSCLC, were randomly assigned 1:1 to receive 240 mg toripalimab or placebo combined with chemotherapy Q3W for 3 cycles before surgery and one cycle after surgery, followed by toripalimab or placebo monotherapy Q3W for 13 cycles. Stratification variables for randomization included disease stage, histopathologic subtype, PD-L1 expression and surgical procedure. Primary endpoints were EFS by investigator and major pathological response (MPR) rate by a blinded independent pathologic review (BIPR) in the stage III and the ITT populations. Secondary endpoints included overall survival (OS), pathologic complete response (pCR) rate, EFS by independent review committee (IRC), and safety. A planned interim analysis was performed on the primary endpoint of EFS in the stage III subjects. Results: A total of 404 patients with stage III NSCLC were randomly assigned to toripalimab (n=202) or placebo (n=202). By the data cutoff date (November 30, 2022), the median follow-up was 18.3 months. Baseline characteristics were well balanced between the two arms. EFS was significantly improved in the toripalimab arm, HR=0.40, 95% CI (0.277-0.565), P<0.0001, and crossed the pre-specified efficacy boundary. The median EFS was not reached in the toripalimab arm and 15.1 months in the placebo arm. A consistent effect on EFS, favoring toripalimab, was observed in all subgroups. The MPR and pCR rates per BIPR were also higher in the toripalimab arm, 48.5% vs 8.4% and 24.8% vs 1.0%, respectively. The OS results showed a trend favoring toripalimab. The incidence of Grade ≥3 adverse events (AEs) (63.4% vs 54.0%), fatal AEs related to toripalimab/placebo (0.5% vs 0%) and AEs leading to discontinuation of toripalimab/placebo (9.4% vs 7.4%) were comparable between the two arms. However, the incidence of immune-related AEs (42.1% vs 22.8%) was more frequent in the toripalimab arm. Conclusions: The addition of toripalimab to perioperative chemotherapy showed statistically significant improvements in EFS for patients with stage III NSCLC with a manageable safety profile. Patients will be followed for overall survival. Clinical trial information: NCT04158440 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小蘑菇的应助被劳小呆采纳,获得10
刚刚
ajing发布了新的文献求助20
1秒前
1秒前
2秒前
科研通AI6.2的应助被XZM采纳,获得10
2秒前
2秒前
sing完成签到 ,获得积分10
3秒前
3秒前
Mortal完成签到 ,获得积分10
4秒前
4秒前
纯真正豪发布了新的文献求助10
6秒前
酷波er的应助被JXY189采纳,获得10
6秒前
6秒前
香蕉觅云的应助被长庚采纳,获得10
6秒前
研友_ngqgY8完成签到,获得积分10
7秒前
8秒前
初(*^▽^*)心的应助被李宏梅采纳,获得10
9秒前
章鱼发布了新的文献求助10
10秒前
11秒前
Steven发布了新的文献求助30
12秒前
13秒前
啊呜完成签到,获得积分10
13秒前
可靠的马丁完成签到,获得积分10
14秒前
Maestro_S的应助被沈恺恺采纳,获得10
15秒前
15秒前
15秒前
ingst完成签到 ,获得积分10
16秒前
大佬发布了新的文献求助10
17秒前
万能图书馆的应助被FZ采纳,获得10
18秒前
AAA袁氏茶馆完成签到,获得积分10
18秒前
无花果的应助被刘白采纳,获得10
18秒前
水煮电吹风的应助被LL采纳,获得10
18秒前
裴腾骏完成签到,获得积分10
18秒前
19秒前
科研通AI6.2的应助被zo采纳,获得10
20秒前
20秒前
浮云客发布了新的文献求助10
24秒前
24秒前
ChoHing发布了新的文献求助10
24秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500